These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9408807

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
    Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, Salazar DE.
    Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
    Awni WM, Cavanaugh JH, Leese P, Kasier J, Cao G, Locke CS, Dube LM.
    Eur J Clin Pharmacol; 1997 Mar; 52(1):49-54. PubMed ID: 9143867
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
    von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI.
    J Clin Psychopharmacol; 1996 Apr; 16(2):104-12. PubMed ID: 8690825
    [Abstract] [Full Text] [Related]

  • 7. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
    Robbins B, Chang CT, Cramer JA, Garreffa S, Hafkin B, Hunt TL, Meligeni J.
    Clin Pharmacol Ther; 1996 Mar; 59(3):275-83. PubMed ID: 8653990
    [Abstract] [Full Text] [Related]

  • 8. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.
    Wong SL, Cao G, Mack R, Granneman GR.
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):146-51. PubMed ID: 9562230
    [Abstract] [Full Text] [Related]

  • 9. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.
    Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS.
    Eur J Clin Pharmacol; 1997 Mar; 52(4):311-5. PubMed ID: 9248771
    [Abstract] [Full Text] [Related]

  • 10. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J, Tatami S, Tsuda Y, Mattheus M, Mehlburger L, Wein M, Michel MC.
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [Abstract] [Full Text] [Related]

  • 11. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
    Saruwatari J, Yasui-Furukori N, Niioka T, Akamine Y, Takashima A, Kaneko S, Uno T.
    J Clin Psychopharmacol; 2012 Apr; 32(2):195-9. PubMed ID: 22367658
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.
    Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR.
    JAMA; 2012 Apr; 269(12):1513-8. PubMed ID: 8445813
    [Abstract] [Full Text] [Related]

  • 14. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine.
    Stern RH, Smithers JA, Olson SC.
    J Clin Pharmacol; 1998 Aug; 38(8):753-7. PubMed ID: 9725552
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
    Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V.
    Clin Ther; 2001 Mar; 23(3):451-66. PubMed ID: 11318079
    [Abstract] [Full Text] [Related]

  • 16. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram.
    Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL.
    Clin Pharmacol Ther; 1996 Apr; 59(4):383-8. PubMed ID: 8612381
    [Abstract] [Full Text] [Related]

  • 17. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers.
    Briciu C, Neag M, Muntean D, Vlase L, Bocsan C, Buzoianu A, Gheldiu AM, Achim M, Popa A.
    J Clin Pharm Ther; 2014 Oct; 39(5):535-40. PubMed ID: 24845234
    [Abstract] [Full Text] [Related]

  • 18. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.
    Banfield C, Herron J, Keung A, Padhi D, Affrime M.
    Clin Pharmacokinet; 2002 Oct; 41 Suppl 1():37-44. PubMed ID: 12169045
    [Abstract] [Full Text] [Related]

  • 19. Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine.
    Pesco-Koplowitz L, Hassell A, Lee P, Zhou H, Hall N, Wiesinger B, Mechlinski W, Grover M, Hunt T, Smith R, Travers S.
    J Clin Pharmacol; 1999 Jan; 39(1):76-85. PubMed ID: 9987703
    [Abstract] [Full Text] [Related]

  • 20. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
    Stout SM, Nielsen J, Bleske BE, Shea M, Brook R, Kerber K, Welage LS.
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):373-9. PubMed ID: 20705902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.